CLEVELAND, Oct. 26 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc.
Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., stated, "We are delighted to have Dr. Gordon join our drug development team. His expertise in pharmaceutical drug development and experience in preparing New Drug Applications (NDAs) for FDA approval will be invaluable as we move our first products into clinical trials."
Dr. Gordon brings more than 17 years of clinical research experience and 13 years of pharmaceutical industry experience to Cleveland BioLabs. Most recently, Dr. Gordon held the position of Associate Director CNS, Clinical Development and Medical Affairs at Forest Research Institute, a division of Forest Laboratories, Inc.). Prior to this, he was Clinical Research Scientist, CNS Clinical Development at Pharmacia Corp. and Clinical Project Manager at Fujisawa Pharmaceutical Co., Ltd. Dr. Gordon's first pharmaceutical position was as Director of Clinical Research at Cancer Treatment Centers of America. Dr. Gordon received his Ph.D. in Pharmacology from the University of Kansas Medical School. Dr. Gordon has authored or co- authored 54 peer reviewed journal articles, 5 invited book chapters, 3 software manuals, and 56 abstracts.
Dr. Gordon stated, "I am excited to join Cleveland BioLabs at this critical time in the Company's development. The potential demonstrated by the Company's lead compounds is compelling and I look forward to contributing to their progress."
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."
Contact:
The Global Consulting Group
Rachel Levine
T: (646) 284-9439
E: rlevine@hfgcg.com